Navigation Links
Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy

o clinical studies of pixantrone in aggressive NHL patients, RAPID and a phase III single agent trial, known as EXTEND. The EXTEND trial explores the role of single-agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens. Patients are randomized to receive either pixantrone or another single-agent drug of the physician's choice currently used for the treatment of this patient population. An interim look for the EXTEND trial is planned for later this year.

The Company is awaiting feedback from the FDA on the design of a new phase III trial of pixantrone for patients with indolent NHL. The trial, PIX303, will examine the complete remission rates and time to disease progression for the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of fludarabine and rituximab (F-R) in the treatment of patients who have received at least one prior treatment for NHL. The trial is expected to enroll 300 patients.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and permit simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For ad
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
4. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
5. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
6. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
10. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
11. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Post Your Comments:
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... quarter and fiscal year ended June 30, 2014 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Published in the September 18th New England Journal of,Medicine, ... colorectal cancer. Many,of these deaths could be prevented by ... older who should be screened for the disease are,not ... and safety,concerns associated with current screening exams., However, ...
... 17 The Department of,Justice announced today that ... CEO,Roundtable on Cancer (CRC) to develop and publicize ... cancer treatments. The Department said,the language is not ... to help,increase efficiency in contract negotiations, potentially reducing ...
Cached Medicine Technology:MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy 2Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:7/11/2014)... According to new report "C4ISR Market ... to register a CAGR of 2.28% to reach ... data tables and 76 figures spread through 185 ... http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers will receive 10% ... The report provides market analysis of the global ...
(Date:7/11/2014)... 11, 2014 As transvaginal mesh ... Johnson & Johnson’s Ethicon Inc. unit continue to ... that the Texas Attorney General’s Office has acknowledged ... surgical mesh products used to treat pelvic organ ... report from kens5.com, the probe began nearly two ...
(Date:7/11/2014)... -- Reducing the number of deer in an area ... other tick-borne infections among people, new research indicates. ... to reduce human interactions with deer, infected nymphal ticks ... wrote. White-tailed deer are the primary host for ... The study included nearly all the permanent residents ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... who was thought to be cured by immediate and aggressive ... of the AIDS-causing virus in her bloodstream, disappointed federal officials ... old, had remained virus-free even though she stopped taking HIV ... her remission would open the door to a functional cure ...
(Date:7/11/2014)... 11, 2014 Microbiology testing is a ... diagnostics industry, which is expected to pose the biggest ... sector owes its growth to the ongoing spread of ... worldwide and a major factor leading to the upsurge ... bio-terrorism, and a broader availability of immunosuppressants, among others. ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3
... , MONDAY, Dec. 19 (HealthDay News) -- A new analysis on ... cuts fracture risk in older adults, but only when taken with ... D -- present in a small number of foods and produced ... Preventive Services Task Force (USPSTF) also indicates that it,s too soon ...
... jeopardize access to medical care for many millions ... the American College of Physicians (ACP) in a ... Senate leadership. ACP is the largest physician ... United States, representing 132,000 internal medicine specialist physicians ...
... have discovered a missing link between the body,s biological ... help avoid the serious side effects of drugs used ... paper published last week in Nature, scientists at the ... that control the body,s biological rhythms, known as cryptochromes, ...
... , MONDAY, Dec. 19 (HealthDay News) -- Blood ... for heart disease and stroke, a new study suggests. ... pressure readings were tracked for an average of 14 years. ... normal levels by age 55 had the lowest lifetime risk ...
... mice suggest that blocking the production of small molecules ... may represent a novel strategy for treating cancer by ... research is the first to show that EETs work ... protein known to induce blood vessel growth. Together, EETs ...
... naturally in the body from a major component of ... are currently in clinical trials for the treatment of ... led by Dipak Panigrahy and Mark Kieran, at ... Institute for Systems Biology, Seattle; and Darryl Zeldin, at ...
Cached Medicine News:Health News:Vitamin D Helps Bone Health Only With Calcium: Report 2Health News:Vitamin D Helps Bone Health Only With Calcium: Report 3Health News:Congress' 'disarray' makes it 'likely' that 27 percent Medicare cut will go in effect 2Health News:Salk discovery may lead to safer treatments for asthma, allergies and arthritis 2Health News:Salk discovery may lead to safer treatments for asthma, allergies and arthritis 3Health News:Blood Pressure Control in Middle Age Can Lower Lifetime Heart Risk 2Health News:NIH scientists find a potential new avenue for cancer therapies 2Health News:NIH scientists find a potential new avenue for cancer therapies 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: